The first of two dozen chapters introduces the need for new antifungal medicines due to opportunistic fungal infections rising among immunocompromised patients and side-effects of present drugs. Rai (biotechnology, Amravati U., Maharashta U., India); Mares (biology-botany, U. of Ferrara, Italy); and other scientists discuss such topics as improved
The first of two dozen chapters introduces the need for new antifungal medicines due to opportunistic fungal infections rising among immunocompromised...
